Recombinant human C1-inhibitor protects against brain ischemia/reperfusion injury with a wide time-window of efficacy

Claudio Storini, Raffaella Gesuete, Emanuela Rossi, Alessandro Fantin, Luigi Bergamaschini, Bertjan Ziere, Helene Vietsch, Maria Grazia De Simoni

Research output: Contribution to journalArticle

Abstract

We have previously shown that plasma derived C1-INH (pdC1-INH), the endogenous inhibitor of complement and contact/kinin system, has potent neuroprotective effects in ischemic mice, although with a narrow time-window of efficacy(1-3). This inhibitor, currently used to manage angioedema attacks in patients with hereditary or acquired C1-INH deficiency (angioedema, HAE or AAE), is purifed from human plasma. Using a plasma derived molecule can be disadvantageous, due to risks for human pathogenic viruses contamination and to difficulties in supply and purification. Due to these limitations, a recombinant approach was chosen to overcome these problems. Recombinant human C1-INH (rhC1-INH, Pharming Technologies B.V.) has been administrated intravenously to C57Bl/6 ischemic mice at different doses (5, 10 and 15U/mouse) and time-points (0, 3, 6, 18 and 24 hours) from transient ischemia. Forty-eight hours after ischemia, rhC1-INH, at the dose of 15U/mouse, was able to markedly improve the cerebral damage when administrated 0, 3 and 6h from ischemia (13.67±2.59 mm3, 11.71±0.63mm3 and 20.38±2.37mm3, respectively) compared to saline-treated ischemic mice (44.43±5.94mm3). Also when administrated 18 hours after ischemia, rhC1-INH was still significantly effective (27.13±2.58mm3). Fluoro jade staining showed that amelioration of cerebral damage was due to an effective sparing of neurons. Immunohistochemistry for macroglia/macrohages (anti-CD11b) and astrocytes (anti-GFAP) showed that rhC1-INH was able to counteract the microglial and astrocytic activation, as well as macrophage infiltration. Analysis of rhC1-INH localization in the brain by confocal microscopy revealed that rhC1-INH was confined to cerebral vessels and that it was able to bind endothelial cells as shown by colocalization with Claudin-5 and ICAM-1. These data demonstrate that rhC1-INH has an important neuroprotective action with a wider time-window of efficacy compared to pdC1-INH. This favorable profile of rhC1-INH is probably related to a different glycosylation of the native versus recombinant molecules.

Original languageEnglish
JournalJournal of Cerebral Blood Flow and Metabolism
Volume27
Issue numberSUPPL. 1
Publication statusPublished - Nov 13 2007

Fingerprint

Reperfusion Injury
Brain Ischemia
Ischemia
Angioedema
Complement Inactivating Agents
Claudin-5
Kinins
Neuroprotective Agents
Intercellular Adhesion Molecule-1
Glycosylation
Confocal Microscopy
Astrocytes
Endothelial Cells
Immunohistochemistry
Macrophages
human SERPING1 protein
Staining and Labeling
Viruses
Technology
Neurons

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)
  • Endocrinology, Diabetes and Metabolism

Cite this

Recombinant human C1-inhibitor protects against brain ischemia/reperfusion injury with a wide time-window of efficacy. / Storini, Claudio; Gesuete, Raffaella; Rossi, Emanuela; Fantin, Alessandro; Bergamaschini, Luigi; Ziere, Bertjan; Vietsch, Helene; De Simoni, Maria Grazia.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 27, No. SUPPL. 1, 13.11.2007.

Research output: Contribution to journalArticle

Storini, Claudio ; Gesuete, Raffaella ; Rossi, Emanuela ; Fantin, Alessandro ; Bergamaschini, Luigi ; Ziere, Bertjan ; Vietsch, Helene ; De Simoni, Maria Grazia. / Recombinant human C1-inhibitor protects against brain ischemia/reperfusion injury with a wide time-window of efficacy. In: Journal of Cerebral Blood Flow and Metabolism. 2007 ; Vol. 27, No. SUPPL. 1.
@article{10ef931fa1b14d57aa5c661c12c3c2f4,
title = "Recombinant human C1-inhibitor protects against brain ischemia/reperfusion injury with a wide time-window of efficacy",
abstract = "We have previously shown that plasma derived C1-INH (pdC1-INH), the endogenous inhibitor of complement and contact/kinin system, has potent neuroprotective effects in ischemic mice, although with a narrow time-window of efficacy(1-3). This inhibitor, currently used to manage angioedema attacks in patients with hereditary or acquired C1-INH deficiency (angioedema, HAE or AAE), is purifed from human plasma. Using a plasma derived molecule can be disadvantageous, due to risks for human pathogenic viruses contamination and to difficulties in supply and purification. Due to these limitations, a recombinant approach was chosen to overcome these problems. Recombinant human C1-INH (rhC1-INH, Pharming Technologies B.V.) has been administrated intravenously to C57Bl/6 ischemic mice at different doses (5, 10 and 15U/mouse) and time-points (0, 3, 6, 18 and 24 hours) from transient ischemia. Forty-eight hours after ischemia, rhC1-INH, at the dose of 15U/mouse, was able to markedly improve the cerebral damage when administrated 0, 3 and 6h from ischemia (13.67±2.59 mm3, 11.71±0.63mm3 and 20.38±2.37mm3, respectively) compared to saline-treated ischemic mice (44.43±5.94mm3). Also when administrated 18 hours after ischemia, rhC1-INH was still significantly effective (27.13±2.58mm3). Fluoro jade staining showed that amelioration of cerebral damage was due to an effective sparing of neurons. Immunohistochemistry for macroglia/macrohages (anti-CD11b) and astrocytes (anti-GFAP) showed that rhC1-INH was able to counteract the microglial and astrocytic activation, as well as macrophage infiltration. Analysis of rhC1-INH localization in the brain by confocal microscopy revealed that rhC1-INH was confined to cerebral vessels and that it was able to bind endothelial cells as shown by colocalization with Claudin-5 and ICAM-1. These data demonstrate that rhC1-INH has an important neuroprotective action with a wider time-window of efficacy compared to pdC1-INH. This favorable profile of rhC1-INH is probably related to a different glycosylation of the native versus recombinant molecules.",
author = "Claudio Storini and Raffaella Gesuete and Emanuela Rossi and Alessandro Fantin and Luigi Bergamaschini and Bertjan Ziere and Helene Vietsch and {De Simoni}, {Maria Grazia}",
year = "2007",
month = "11",
day = "13",
language = "English",
volume = "27",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Recombinant human C1-inhibitor protects against brain ischemia/reperfusion injury with a wide time-window of efficacy

AU - Storini, Claudio

AU - Gesuete, Raffaella

AU - Rossi, Emanuela

AU - Fantin, Alessandro

AU - Bergamaschini, Luigi

AU - Ziere, Bertjan

AU - Vietsch, Helene

AU - De Simoni, Maria Grazia

PY - 2007/11/13

Y1 - 2007/11/13

N2 - We have previously shown that plasma derived C1-INH (pdC1-INH), the endogenous inhibitor of complement and contact/kinin system, has potent neuroprotective effects in ischemic mice, although with a narrow time-window of efficacy(1-3). This inhibitor, currently used to manage angioedema attacks in patients with hereditary or acquired C1-INH deficiency (angioedema, HAE or AAE), is purifed from human plasma. Using a plasma derived molecule can be disadvantageous, due to risks for human pathogenic viruses contamination and to difficulties in supply and purification. Due to these limitations, a recombinant approach was chosen to overcome these problems. Recombinant human C1-INH (rhC1-INH, Pharming Technologies B.V.) has been administrated intravenously to C57Bl/6 ischemic mice at different doses (5, 10 and 15U/mouse) and time-points (0, 3, 6, 18 and 24 hours) from transient ischemia. Forty-eight hours after ischemia, rhC1-INH, at the dose of 15U/mouse, was able to markedly improve the cerebral damage when administrated 0, 3 and 6h from ischemia (13.67±2.59 mm3, 11.71±0.63mm3 and 20.38±2.37mm3, respectively) compared to saline-treated ischemic mice (44.43±5.94mm3). Also when administrated 18 hours after ischemia, rhC1-INH was still significantly effective (27.13±2.58mm3). Fluoro jade staining showed that amelioration of cerebral damage was due to an effective sparing of neurons. Immunohistochemistry for macroglia/macrohages (anti-CD11b) and astrocytes (anti-GFAP) showed that rhC1-INH was able to counteract the microglial and astrocytic activation, as well as macrophage infiltration. Analysis of rhC1-INH localization in the brain by confocal microscopy revealed that rhC1-INH was confined to cerebral vessels and that it was able to bind endothelial cells as shown by colocalization with Claudin-5 and ICAM-1. These data demonstrate that rhC1-INH has an important neuroprotective action with a wider time-window of efficacy compared to pdC1-INH. This favorable profile of rhC1-INH is probably related to a different glycosylation of the native versus recombinant molecules.

AB - We have previously shown that plasma derived C1-INH (pdC1-INH), the endogenous inhibitor of complement and contact/kinin system, has potent neuroprotective effects in ischemic mice, although with a narrow time-window of efficacy(1-3). This inhibitor, currently used to manage angioedema attacks in patients with hereditary or acquired C1-INH deficiency (angioedema, HAE or AAE), is purifed from human plasma. Using a plasma derived molecule can be disadvantageous, due to risks for human pathogenic viruses contamination and to difficulties in supply and purification. Due to these limitations, a recombinant approach was chosen to overcome these problems. Recombinant human C1-INH (rhC1-INH, Pharming Technologies B.V.) has been administrated intravenously to C57Bl/6 ischemic mice at different doses (5, 10 and 15U/mouse) and time-points (0, 3, 6, 18 and 24 hours) from transient ischemia. Forty-eight hours after ischemia, rhC1-INH, at the dose of 15U/mouse, was able to markedly improve the cerebral damage when administrated 0, 3 and 6h from ischemia (13.67±2.59 mm3, 11.71±0.63mm3 and 20.38±2.37mm3, respectively) compared to saline-treated ischemic mice (44.43±5.94mm3). Also when administrated 18 hours after ischemia, rhC1-INH was still significantly effective (27.13±2.58mm3). Fluoro jade staining showed that amelioration of cerebral damage was due to an effective sparing of neurons. Immunohistochemistry for macroglia/macrohages (anti-CD11b) and astrocytes (anti-GFAP) showed that rhC1-INH was able to counteract the microglial and astrocytic activation, as well as macrophage infiltration. Analysis of rhC1-INH localization in the brain by confocal microscopy revealed that rhC1-INH was confined to cerebral vessels and that it was able to bind endothelial cells as shown by colocalization with Claudin-5 and ICAM-1. These data demonstrate that rhC1-INH has an important neuroprotective action with a wider time-window of efficacy compared to pdC1-INH. This favorable profile of rhC1-INH is probably related to a different glycosylation of the native versus recombinant molecules.

UR - http://www.scopus.com/inward/record.url?scp=36348986034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36348986034&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:36348986034

VL - 27

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - SUPPL. 1

ER -